{
  "file_name": "CUAD_v1/full_contract_pdf\\Part_I\\Development\\CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement.pdf",
  "annotations": [
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Document Name_0",
      "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
      "answer_text": "Development Agreement",
      "page_number": 0,
      "words": [
        {
          "text": "Development Agreement",
          "bbox": [
            1421.0,
            342.0,
            1890.0,
            384.0
          ],
          "confidence": 0.9995174407958984
        }
      ],
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "CNS and WPD are sometimes referred to herein individually as a \"Party\" and collectively as the \"Parties.\"",
      "page_number": 0,
      "words": [
        {
          "text": "WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Zwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are",
          "bbox": [
            279.0,
            506.0,
            3029.0,
            552.0
          ],
          "confidence": 0.9871551990509033
        },
        {
          "text": "sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\".",
          "bbox": [
            279.0,
            566.0,
            1890.0,
            609.0
          ],
          "confidence": 0.9848995804786682
        }
      ],
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "CNS",
      "page_number": 0,
      "words": [
        {
          "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
          "bbox": [
            448.0,
            397.0,
            3027.0,
            439.0
          ],
          "confidence": 0.9855481386184692
        }
      ],
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "WPD Pharmaceuticals",
      "page_number": 0,
      "words": [
        {
          "text": "WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Zwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are",
          "bbox": [
            279.0,
            506.0,
            3029.0,
            552.0
          ],
          "confidence": 0.9871551990509033
        }
      ],
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "CNS Pharmaceuticals, Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
          "bbox": [
            448.0,
            397.0,
            3027.0,
            439.0
          ],
          "confidence": 0.9855481386184692
        },
        {
          "text": "Pharmaceuticals, Inc. (\"CNS'), a Nevada corporation, having a business address of 2100 West Loop South, Suite 900, Houston, Texas 77027, and.",
          "bbox": [
            277.0,
            451.0,
            3029.0,
            497.0
          ],
          "confidence": 0.9846682548522949
        }
      ],
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "WPD",
      "page_number": 0,
      "words": [
        {
          "text": "WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Zwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are",
          "bbox": [
            279.0,
            506.0,
            3029.0,
            552.0
          ],
          "confidence": 0.9871551990509033
        }
      ],
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Agreement Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
      "answer_text": "March 20, 2020",
      "page_number": 0,
      "words": [
        {
          "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
          "bbox": [
            448.0,
            397.0,
            3027.0,
            439.0
          ],
          "confidence": 0.9855481386184692
        }
      ],
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Effective Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effective ",
      "answer_text": "March 20, 2020",
      "page_number": 0,
      "words": [
        {
          "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
          "bbox": [
            448.0,
            397.0,
            3027.0,
            439.0
          ],
          "confidence": 0.9855481386184692
        }
      ],
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Expiration Date_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "The term of this Agreement will commence on the Effective Date and remain in full force and effect until the expiration of the Sublicense Agreement, unless earlier termination by pursuant to the terms of this Agreement (\"Term\").",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1.",
          "bbox": [
            277.0,
            285.0,
            488.0,
            323.0
          ],
          "confidence": 0.9286127686500549
        },
        {
          "text": "Development Agreement",
          "bbox": [
            1421.0,
            342.0,
            1890.0,
            384.0
          ],
          "confidence": 0.9995174407958984
        },
        {
          "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
          "bbox": [
            448.0,
            397.0,
            3027.0,
            439.0
          ],
          "confidence": 0.9855481386184692
        },
        {
          "text": "Pharmaceuticals, Inc. (\"CNS'), a Nevada corporation, having a business address of 2100 West Loop South, Suite 900, Houston, Texas 77027, and.",
          "bbox": [
            277.0,
            451.0,
            3029.0,
            497.0
          ],
          "confidence": 0.9846682548522949
        },
        {
          "text": "WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Zwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are",
          "bbox": [
            279.0,
            506.0,
            3029.0,
            552.0
          ],
          "confidence": 0.9871551990509033
        },
        {
          "text": "sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\".",
          "bbox": [
            279.0,
            566.0,
            1890.0,
            609.0
          ],
          "confidence": 0.9848995804786682
        },
        {
          "text": "RECITALS",
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ],
          "confidence": 0.9994499683380127
        },
        {
          "text": "WHEREAS, WPD is party to a sublicense agreement dated February 19, 2019 with Moleculin Biotech, Inc. (\"MBI) (the \"Sublicense",
          "bbox": [
            448.0,
            676.0,
            3025.0,
            718.0
          ],
          "confidence": 0.9924393892288208
        },
        {
          "text": "Agreement') to research and develop, manufacture, have manufactured, use, export/import, offer to sell and/or sell certain products for use in",
          "bbox": [
            279.0,
            735.0,
            3029.0,
            777.0
          ],
          "confidence": 0.9946522116661072
        },
        {
          "text": "certain territories;",
          "bbox": [
            277.0,
            795.0,
            605.0,
            831.0
          ],
          "confidence": 0.9829395413398743
        },
        {
          "text": "WHEREAS, WPD is developing certain anti-viral indications pursuant to the Sublicense Agreement; and",
          "bbox": [
            446.0,
            846.0,
            2402.0,
            890.0
          ],
          "confidence": 0.9923189878463745
        },
        {
          "text": "WHEREAS, CNS has agreed to fund a portion of the development of such indications in exchange for certain economic rights..",
          "bbox": [
            448.0,
            903.0,
            2791.0,
            945.0
          ],
          "confidence": 0.9883580207824707
        },
        {
          "text": "NOW, THEREFORE, in consideration of the covenants, conditions and agreements hereinafter set forth, and other valuable consideration,",
          "bbox": [
            440.0,
            958.0,
            3025.0,
            1001.0
          ],
          "confidence": 0.9950847029685974
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, WPD and CNS hereby agree as follows:.",
          "bbox": [
            279.0,
            1016.0,
            2170.0,
            1058.0
          ],
          "confidence": 0.9944117665290833
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ],
          "confidence": 0.9448484778404236
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ],
          "confidence": 0.9979127645492554
        },
        {
          "text": "1.1 \"Approval Achievement Date\"' means the earlier of the: (i) date on which WPD receives marketing approval for a Development Product",
          "bbox": [
            446.0,
            1180.0,
            3029.0,
            1226.0
          ],
          "confidence": 0.9900801777839661
        },
        {
          "text": "Development Fees hereunder of $1.0 million..",
          "bbox": [
            279.0,
            1296.0,
            1100.0,
            1336.0
          ],
          "confidence": 0.9840089678764343
        },
        {
          "text": "1.2 \"Business Day\"' means any day other than a day which is a Saturday, a Sunday or any other day on which banks are authorized or",
          "bbox": [
            444.0,
            1349.0,
            3027.0,
            1394.0
          ],
          "confidence": 0.9931846261024475
        },
        {
          "text": "required to be closed in New York City, NY..",
          "bbox": [
            276.0,
            1407.0,
            1073.0,
            1449.0
          ],
          "confidence": 0.9924694299697876
        },
        {
          "text": "1.3 \"Calendar Quarter\"' means the consecutive three month period ending on one of March 31, June 30, September 30, or December 31.",
          "bbox": [
            446.0,
            1466.0,
            2934.0,
            1502.0
          ],
          "confidence": 0.9857224822044373
        },
        {
          "text": "1.4 \"Confidential Information\"' includes: (1) all information contained in documents marked \"confidential\" and disclosed by one Party (the",
          "bbox": [
            444.0,
            1517.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9882820248603821
        },
        {
          "text": "\"disclosing party\") to the other Party (the \"recipient party\") pursuant to this Agreement; (2) orally disclosed information which is disclosed by the",
          "bbox": [
            279.0,
            1573.0,
            3027.0,
            1619.0
          ],
          "confidence": 0.9915019869804382
        },
        {
          "text": "disclosing party to the recipient party pursuant to this Agreement, summarized in writing, identified as \"confidential\" and delivered to the recipient",
          "bbox": [
            277.0,
            1630.0,
            3029.0,
            1676.0
          ],
          "confidence": 0.9962403178215027
        },
        {
          "text": "party; and (3) all proprietary technical information, business and financial information, and all other information which a reasonable person would",
          "bbox": [
            277.0,
            1687.0,
            3029.0,
            1732.0
          ],
          "confidence": 0.9834481477737427
        },
        {
          "text": "treat confidentially that relates to the Development Products and disclosed from the disclosing party to the recipient party, whether or not the",
          "bbox": [
            277.0,
            1745.0,
            3027.0,
            1789.0
          ],
          "confidence": 0.9876152873039246
        },
        {
          "text": "information is marked as \"confidential.\" Notwithstanding anything to the contrary, CNS shall be permitted to make such disclosures as CNS",
          "bbox": [
            277.0,
            1798.0,
            3027.0,
            1844.0
          ],
          "confidence": 0.9905795454978943
        },
        {
          "text": "determines, in its sole discretion, is required pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof..",
          "bbox": [
            279.0,
            1857.0,
            2958.0,
            1899.0
          ],
          "confidence": 0.9846920371055603
        },
        {
          "text": "1.5 \"Development Fee'\" means 50% of the Net Sales for any Development Products in the Development Territory..",
          "bbox": [
            446.0,
            1908.0,
            2543.0,
            1957.0
          ],
          "confidence": 0.9791620373725891
        },
        {
          "text": "1.6 \"Development Products\" means: (i) Sublicensed Products, as defined in the Sublicense Agreement, in the field of pharmaceutical drug",
          "bbox": [
            448.0,
            1970.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9852625131607056
        },
        {
          "text": "products for the treatment of any viral infection in humans; and (ii) any other drug or product in the field of pharmaceutical drug products for the",
          "bbox": [
            279.0,
            2027.0,
            3027.0,
            2069.0
          ],
          "confidence": 0.9874441027641296
        },
        {
          "text": "treatment of any viral infection in humans that is licensed between WPD and MBI after this date..",
          "bbox": [
            279.0,
            2083.0,
            2077.0,
            2120.0
          ],
          "confidence": 0.984982430934906
        },
        {
          "text": "1.7 \"Development Territory\"' means (i) until the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense.",
          "bbox": [
            442.0,
            2134.0,
            3027.0,
            2180.0
          ],
          "confidence": 0.9841306209564209
        },
        {
          "text": "Agreement; and (ii) after the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement, other than Poland..",
          "bbox": [
            283.0,
            2195.0,
            2962.0,
            2237.0
          ],
          "confidence": 0.9880318641662598
        },
        {
          "text": "1",
          "bbox": [
            1641.0,
            2277.0,
            1670.0,
            2311.0
          ],
          "confidence": 0.9987025260925293
        },
        {
          "text": "Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020",
          "bbox": [
            332.0,
            4437.0,
            1421.0,
            4479.0
          ],
          "confidence": 0.9964609146118164
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Expiration Date_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "The term of this Agreement will commence on the Effective Date and remain in full force and effect until the expiration of the Sublicense Agreement, unless earlier termination by pursuant to the terms of this Agreement (\"Term\").",
      "page_number": 1,
      "words": [
        {
          "text": "1.8 \"Net Sales\"' shall be defined in the same way as defined in Sections 6.1 (a)-(f) of the Sublicense Agreement, as applicable only to the",
          "bbox": [
            450.0,
            258.0,
            3025.0,
            300.0
          ],
          "confidence": 0.9870871305465698
        },
        {
          "text": "Agreement.",
          "bbox": [
            283.0,
            373.0,
            498.0,
            411.0
          ],
          "confidence": 0.999921977519989
        },
        {
          "text": "1.9 \"Phase II Milestone Payment' means the completion by WPD of a Phase II Study in one of the countries included within the.",
          "bbox": [
            442.0,
            422.0,
            3027.0,
            468.0
          ],
          "confidence": 0.989180862903595
        },
        {
          "text": "Development Territory, which clinical trial meets all endpoints and is sufficient to form the basis of an application for approval of a Development.",
          "bbox": [
            279.0,
            482.0,
            3029.0,
            524.0
          ],
          "confidence": 0.9877327680587769
        },
        {
          "text": "Product in one Development Territory other than Poland..",
          "bbox": [
            281.0,
            541.0,
            1336.0,
            577.0
          ],
          "confidence": 0.9897002577781677
        },
        {
          "text": "1.10 \"Sale\", \"Sells\", \"Sold\"' means the transfer or disposition of a Development Product, for value, to a person or entity for end use.",
          "bbox": [
            448.0,
            594.0,
            2880.0,
            636.0
          ],
          "confidence": 0.9865548610687256
        },
        {
          "text": "ARTICLE 2",
          "bbox": [
            1544.0,
            649.0,
            1767.0,
            687.0
          ],
          "confidence": 0.9926357269287109
        },
        {
          "text": "DEVELOPMENT AGREEMENT",
          "bbox": [
            1350.0,
            707.0,
            1954.0,
            744.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "take, or cause to be taken, all actions, and to do or cause to be done, all things necessary, proper or desirable or advisable under applicable laws to.",
          "bbox": [
            277.0,
            817.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9957833290100098
        },
        {
          "text": "develop and commercialize the Development Products, with a goal of eventual approval of Development Products in the Development Territory. In",
          "bbox": [
            281.0,
            875.0,
            3025.0,
            916.0
          ],
          "confidence": 0.9946615695953369
        },
        {
          "text": "exchange for the payment by WPD of the Development Fee to CNS, CNS hereby agrees to pay WPD the following payments: (i) within thirty",
          "bbox": [
            277.0,
            930.0,
            3027.0,
            976.0
          ],
          "confidence": 0.9964195489883423
        },
        {
          "text": "Business Days from the date of this Agreement, CNS will make an upfront payment of $225,000 to WPD; and (ii) within thirty days of the verified",
          "bbox": [
            279.0,
            985.0,
            3027.0,
            1027.0
          ],
          "confidence": 0.9940240979194641
        },
        {
          "text": "achievement of the Phase II Milestone, (such verification shall be conducted by an independent third party mutually acceptable to the parties",
          "bbox": [
            277.0,
            1042.0,
            3027.0,
            1085.0
          ],
          "confidence": 0.9979512095451355
        },
        {
          "text": "hereto), CNS will make a payment of $775,000 to WPD.",
          "bbox": [
            277.0,
            1098.0,
            1285.0,
            1142.0
          ],
          "confidence": 0.9748402833938599
        },
        {
          "text": "2.2 If after three years from the Effective Date of this Development Agreement, WPD fails to use commercially reasonable efforts as set",
          "bbox": [
            444.0,
            1155.0,
            3030.0,
            1197.0
          ],
          "confidence": 0.9947488307952881
        },
        {
          "text": "forth in section 2.1 above, CNS shall have the right to terminate this Agreement pursuant to the terms specified in Section 6.2 below, and CNS shall",
          "bbox": [
            279.0,
            1212.0,
            3029.0,
            1254.0
          ],
          "confidence": 0.9961009621620178
        },
        {
          "text": "be entitled to the return of any payments made hereunder. For the purpose of this clause, if WPD has expended the funds provided by CNS",
          "bbox": [
            274.0,
            1263.0,
            3029.0,
            1314.0
          ],
          "confidence": 0.9811084866523743
        },
        {
          "text": "pursuant to section 2.1 above on developing anti-viral indications (including all direct and indirect costs of such development), it will be deemed to.",
          "bbox": [
            277.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9939746260643005
        },
        {
          "text": "have used commercially reasonable efforts in good faith.",
          "bbox": [
            276.0,
            1380.0,
            1329.0,
            1424.0
          ],
          "confidence": 0.9941956400871277
        },
        {
          "text": "2.3 The first Development Fees payment shall be due forty-five days after the end of the Calendar Quarter in which the first Sale of a.",
          "bbox": [
            440.0,
            1431.0,
            3029.0,
            1482.0
          ],
          "confidence": 0.992863655090332
        },
        {
          "text": "Development Product took place. Thereafter, WPD shall furnish to CNS Development Fees no later than forty-five days after the end of each",
          "bbox": [
            277.0,
            1491.0,
            3027.0,
            1533.0
          ],
          "confidence": 0.9914149641990662
        },
        {
          "text": "Calendar Quarter for the Sale of Development Products through the end of such Calendar Quarter and shall further furnish CNS with a written",
          "bbox": [
            279.0,
            1548.0,
            3027.0,
            1590.0
          ],
          "confidence": 0.998877227306366
        },
        {
          "text": "statement setting forth an accounting showing the calculation of the Development Fees..",
          "bbox": [
            277.0,
            1604.0,
            1919.0,
            1646.0
          ],
          "confidence": 0.9940059185028076
        },
        {
          "text": "ARTICLE 3",
          "bbox": [
            1544.0,
            1661.0,
            1767.0,
            1699.0
          ],
          "confidence": 0.9958580732345581
        },
        {
          "text": "INFORMATION AND USE",
          "bbox": [
            1401.0,
            1718.0,
            1909.0,
            1754.0
          ],
          "confidence": 0.9995668530464172
        },
        {
          "text": "Sublicense Agreement related to the Development Products on a quarterly basis..",
          "bbox": [
            277.0,
            1825.0,
            1782.0,
            1873.0
          ],
          "confidence": 0.9869390726089478
        },
        {
          "text": "3.2 The Parties agree to a mutual exchange of any data, information or know-how resulting from the research and development of the.",
          "bbox": [
            444.0,
            1882.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.9899076223373413
        },
        {
          "text": "Development Products.",
          "bbox": [
            277.0,
            1939.0,
            712.0,
            1985.0
          ],
          "confidence": 0.9925432801246643
        },
        {
          "text": "ARTICLE 4",
          "bbox": [
            1544.0,
            1997.0,
            1767.0,
            2036.0
          ],
          "confidence": 0.9490203857421875
        },
        {
          "text": "OTHER COMPENSATION",
          "bbox": [
            1399.0,
            2054.0,
            1910.0,
            2090.0
          ],
          "confidence": 0.9996956586837769
        },
        {
          "text": "4.1 If MBI exercises its right to terminate the Sublicense Agreement in whole, or to remove a portion of the sublicensed subject matter that.",
          "bbox": [
            444.0,
            2105.0,
            3029.0,
            2153.0
          ],
          "confidence": 0.9973670244216919
        },
        {
          "text": "relates to some or all of the Development Products, by paying to WPD the Buyback Consideration (as defined in the Sublicense Agreement), wPD",
          "bbox": [
            276.0,
            2165.0,
            3027.0,
            2209.0
          ],
          "confidence": 0.9869776964187622
        },
        {
          "text": "agrees that CNS shall receive the greater of (i) 50% of the Buyback Consideration that is attributable to the field of anti-viral pharmaceutical drug",
          "bbox": [
            279.0,
            2222.0,
            3027.0,
            2266.0
          ],
          "confidence": 0.993865966796875
        },
        {
          "text": "products for humans (such attribution to be mutually agreed upon by the Parties), and (ii) the amounts actually provided to WPD pursuant to.",
          "bbox": [
            277.0,
            2279.0,
            3029.0,
            2321.0
          ],
          "confidence": 0.9830725789070129
        },
        {
          "text": "Section 2.1 of this Agreement.",
          "bbox": [
            281.0,
            2337.0,
            837.0,
            2374.0
          ],
          "confidence": 0.989253044128418
        },
        {
          "text": "2",
          "bbox": [
            1642.0,
            2416.0,
            1673.0,
            2454.0
          ],
          "confidence": 0.9953086972236633
        },
        {
          "text": "Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020",
          "bbox": [
            332.0,
            4437.0,
            1421.0,
            4479.0
          ],
          "confidence": 0.9957674741744995
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 2",
          "page": 1,
          "bbox": [
            1544.0,
            649.0,
            1767.0,
            687.0
          ]
        },
        {
          "text": "DEVELOPMENT AGREEMENT",
          "page": 1,
          "bbox": [
            1350.0,
            707.0,
            1954.0,
            744.0
          ]
        },
        {
          "text": "ARTICLE 3",
          "page": 1,
          "bbox": [
            1544.0,
            1661.0,
            1767.0,
            1699.0
          ]
        },
        {
          "text": "INFORMATION AND USE",
          "page": 1,
          "bbox": [
            1401.0,
            1718.0,
            1909.0,
            1754.0
          ]
        },
        {
          "text": "ARTICLE 4",
          "page": 1,
          "bbox": [
            1544.0,
            1997.0,
            1767.0,
            2036.0
          ]
        },
        {
          "text": "OTHER COMPENSATION",
          "page": 1,
          "bbox": [
            1399.0,
            2054.0,
            1910.0,
            2090.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Governing Law_0",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement will be governed by, construed and enforced in accordance with the laws of the State of Texas.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1.",
          "bbox": [
            277.0,
            285.0,
            488.0,
            323.0
          ],
          "confidence": 0.9286127686500549
        },
        {
          "text": "Development Agreement",
          "bbox": [
            1421.0,
            342.0,
            1890.0,
            384.0
          ],
          "confidence": 0.9995174407958984
        },
        {
          "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
          "bbox": [
            448.0,
            397.0,
            3027.0,
            439.0
          ],
          "confidence": 0.9855481386184692
        },
        {
          "text": "Pharmaceuticals, Inc. (\"CNS'), a Nevada corporation, having a business address of 2100 West Loop South, Suite 900, Houston, Texas 77027, and.",
          "bbox": [
            277.0,
            451.0,
            3029.0,
            497.0
          ],
          "confidence": 0.9846682548522949
        },
        {
          "text": "WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Zwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are",
          "bbox": [
            279.0,
            506.0,
            3029.0,
            552.0
          ],
          "confidence": 0.9871551990509033
        },
        {
          "text": "sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\".",
          "bbox": [
            279.0,
            566.0,
            1890.0,
            609.0
          ],
          "confidence": 0.9848995804786682
        },
        {
          "text": "RECITALS",
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ],
          "confidence": 0.9994499683380127
        },
        {
          "text": "WHEREAS, WPD is party to a sublicense agreement dated February 19, 2019 with Moleculin Biotech, Inc. (\"MBI) (the \"Sublicense",
          "bbox": [
            448.0,
            676.0,
            3025.0,
            718.0
          ],
          "confidence": 0.9924393892288208
        },
        {
          "text": "Agreement') to research and develop, manufacture, have manufactured, use, export/import, offer to sell and/or sell certain products for use in",
          "bbox": [
            279.0,
            735.0,
            3029.0,
            777.0
          ],
          "confidence": 0.9946522116661072
        },
        {
          "text": "certain territories;",
          "bbox": [
            277.0,
            795.0,
            605.0,
            831.0
          ],
          "confidence": 0.9829395413398743
        },
        {
          "text": "WHEREAS, WPD is developing certain anti-viral indications pursuant to the Sublicense Agreement; and",
          "bbox": [
            446.0,
            846.0,
            2402.0,
            890.0
          ],
          "confidence": 0.9923189878463745
        },
        {
          "text": "WHEREAS, CNS has agreed to fund a portion of the development of such indications in exchange for certain economic rights..",
          "bbox": [
            448.0,
            903.0,
            2791.0,
            945.0
          ],
          "confidence": 0.9883580207824707
        },
        {
          "text": "NOW, THEREFORE, in consideration of the covenants, conditions and agreements hereinafter set forth, and other valuable consideration,",
          "bbox": [
            440.0,
            958.0,
            3025.0,
            1001.0
          ],
          "confidence": 0.9950847029685974
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, WPD and CNS hereby agree as follows:.",
          "bbox": [
            279.0,
            1016.0,
            2170.0,
            1058.0
          ],
          "confidence": 0.9944117665290833
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ],
          "confidence": 0.9448484778404236
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ],
          "confidence": 0.9979127645492554
        },
        {
          "text": "1.1 \"Approval Achievement Date\"' means the earlier of the: (i) date on which WPD receives marketing approval for a Development Product",
          "bbox": [
            446.0,
            1180.0,
            3029.0,
            1226.0
          ],
          "confidence": 0.9900801777839661
        },
        {
          "text": "Development Fees hereunder of $1.0 million..",
          "bbox": [
            279.0,
            1296.0,
            1100.0,
            1336.0
          ],
          "confidence": 0.9840089678764343
        },
        {
          "text": "1.2 \"Business Day\"' means any day other than a day which is a Saturday, a Sunday or any other day on which banks are authorized or",
          "bbox": [
            444.0,
            1349.0,
            3027.0,
            1394.0
          ],
          "confidence": 0.9931846261024475
        },
        {
          "text": "required to be closed in New York City, NY..",
          "bbox": [
            276.0,
            1407.0,
            1073.0,
            1449.0
          ],
          "confidence": 0.9924694299697876
        },
        {
          "text": "1.3 \"Calendar Quarter\"' means the consecutive three month period ending on one of March 31, June 30, September 30, or December 31.",
          "bbox": [
            446.0,
            1466.0,
            2934.0,
            1502.0
          ],
          "confidence": 0.9857224822044373
        },
        {
          "text": "1.4 \"Confidential Information\"' includes: (1) all information contained in documents marked \"confidential\" and disclosed by one Party (the",
          "bbox": [
            444.0,
            1517.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9882820248603821
        },
        {
          "text": "\"disclosing party\") to the other Party (the \"recipient party\") pursuant to this Agreement; (2) orally disclosed information which is disclosed by the",
          "bbox": [
            279.0,
            1573.0,
            3027.0,
            1619.0
          ],
          "confidence": 0.9915019869804382
        },
        {
          "text": "disclosing party to the recipient party pursuant to this Agreement, summarized in writing, identified as \"confidential\" and delivered to the recipient",
          "bbox": [
            277.0,
            1630.0,
            3029.0,
            1676.0
          ],
          "confidence": 0.9962403178215027
        },
        {
          "text": "party; and (3) all proprietary technical information, business and financial information, and all other information which a reasonable person would",
          "bbox": [
            277.0,
            1687.0,
            3029.0,
            1732.0
          ],
          "confidence": 0.9834481477737427
        },
        {
          "text": "treat confidentially that relates to the Development Products and disclosed from the disclosing party to the recipient party, whether or not the",
          "bbox": [
            277.0,
            1745.0,
            3027.0,
            1789.0
          ],
          "confidence": 0.9876152873039246
        },
        {
          "text": "information is marked as \"confidential.\" Notwithstanding anything to the contrary, CNS shall be permitted to make such disclosures as CNS",
          "bbox": [
            277.0,
            1798.0,
            3027.0,
            1844.0
          ],
          "confidence": 0.9905795454978943
        },
        {
          "text": "determines, in its sole discretion, is required pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof..",
          "bbox": [
            279.0,
            1857.0,
            2958.0,
            1899.0
          ],
          "confidence": 0.9846920371055603
        },
        {
          "text": "1.5 \"Development Fee'\" means 50% of the Net Sales for any Development Products in the Development Territory..",
          "bbox": [
            446.0,
            1908.0,
            2543.0,
            1957.0
          ],
          "confidence": 0.9791620373725891
        },
        {
          "text": "1.6 \"Development Products\" means: (i) Sublicensed Products, as defined in the Sublicense Agreement, in the field of pharmaceutical drug",
          "bbox": [
            448.0,
            1970.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9852625131607056
        },
        {
          "text": "products for the treatment of any viral infection in humans; and (ii) any other drug or product in the field of pharmaceutical drug products for the",
          "bbox": [
            279.0,
            2027.0,
            3027.0,
            2069.0
          ],
          "confidence": 0.9874441027641296
        },
        {
          "text": "treatment of any viral infection in humans that is licensed between WPD and MBI after this date..",
          "bbox": [
            279.0,
            2083.0,
            2077.0,
            2120.0
          ],
          "confidence": 0.984982430934906
        },
        {
          "text": "1.7 \"Development Territory\"' means (i) until the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense.",
          "bbox": [
            442.0,
            2134.0,
            3027.0,
            2180.0
          ],
          "confidence": 0.9841306209564209
        },
        {
          "text": "Agreement; and (ii) after the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement, other than Poland..",
          "bbox": [
            283.0,
            2195.0,
            2962.0,
            2237.0
          ],
          "confidence": 0.9880318641662598
        },
        {
          "text": "1",
          "bbox": [
            1641.0,
            2277.0,
            1670.0,
            2311.0
          ],
          "confidence": 0.9987025260925293
        },
        {
          "text": "Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020",
          "bbox": [
            332.0,
            4437.0,
            1421.0,
            4479.0
          ],
          "confidence": 0.9964609146118164
        }
      ],
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Revenue/Profit Sharing_0",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "The first Development Fees payment shall be due forty-five days after the end of the Calendar Quarter in which the first Sale of a Development Product took place.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1.",
          "bbox": [
            277.0,
            285.0,
            488.0,
            323.0
          ],
          "confidence": 0.9286127686500549
        },
        {
          "text": "Development Agreement",
          "bbox": [
            1421.0,
            342.0,
            1890.0,
            384.0
          ],
          "confidence": 0.9995174407958984
        },
        {
          "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
          "bbox": [
            448.0,
            397.0,
            3027.0,
            439.0
          ],
          "confidence": 0.9855481386184692
        },
        {
          "text": "Pharmaceuticals, Inc. (\"CNS'), a Nevada corporation, having a business address of 2100 West Loop South, Suite 900, Houston, Texas 77027, and.",
          "bbox": [
            277.0,
            451.0,
            3029.0,
            497.0
          ],
          "confidence": 0.9846682548522949
        },
        {
          "text": "WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Zwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are",
          "bbox": [
            279.0,
            506.0,
            3029.0,
            552.0
          ],
          "confidence": 0.9871551990509033
        },
        {
          "text": "sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\".",
          "bbox": [
            279.0,
            566.0,
            1890.0,
            609.0
          ],
          "confidence": 0.9848995804786682
        },
        {
          "text": "RECITALS",
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ],
          "confidence": 0.9994499683380127
        },
        {
          "text": "WHEREAS, WPD is party to a sublicense agreement dated February 19, 2019 with Moleculin Biotech, Inc. (\"MBI) (the \"Sublicense",
          "bbox": [
            448.0,
            676.0,
            3025.0,
            718.0
          ],
          "confidence": 0.9924393892288208
        },
        {
          "text": "Agreement') to research and develop, manufacture, have manufactured, use, export/import, offer to sell and/or sell certain products for use in",
          "bbox": [
            279.0,
            735.0,
            3029.0,
            777.0
          ],
          "confidence": 0.9946522116661072
        },
        {
          "text": "certain territories;",
          "bbox": [
            277.0,
            795.0,
            605.0,
            831.0
          ],
          "confidence": 0.9829395413398743
        },
        {
          "text": "WHEREAS, WPD is developing certain anti-viral indications pursuant to the Sublicense Agreement; and",
          "bbox": [
            446.0,
            846.0,
            2402.0,
            890.0
          ],
          "confidence": 0.9923189878463745
        },
        {
          "text": "WHEREAS, CNS has agreed to fund a portion of the development of such indications in exchange for certain economic rights..",
          "bbox": [
            448.0,
            903.0,
            2791.0,
            945.0
          ],
          "confidence": 0.9883580207824707
        },
        {
          "text": "NOW, THEREFORE, in consideration of the covenants, conditions and agreements hereinafter set forth, and other valuable consideration,",
          "bbox": [
            440.0,
            958.0,
            3025.0,
            1001.0
          ],
          "confidence": 0.9950847029685974
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, WPD and CNS hereby agree as follows:.",
          "bbox": [
            279.0,
            1016.0,
            2170.0,
            1058.0
          ],
          "confidence": 0.9944117665290833
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ],
          "confidence": 0.9448484778404236
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ],
          "confidence": 0.9979127645492554
        },
        {
          "text": "1.1 \"Approval Achievement Date\"' means the earlier of the: (i) date on which WPD receives marketing approval for a Development Product",
          "bbox": [
            446.0,
            1180.0,
            3029.0,
            1226.0
          ],
          "confidence": 0.9900801777839661
        },
        {
          "text": "Development Fees hereunder of $1.0 million..",
          "bbox": [
            279.0,
            1296.0,
            1100.0,
            1336.0
          ],
          "confidence": 0.9840089678764343
        },
        {
          "text": "1.2 \"Business Day\"' means any day other than a day which is a Saturday, a Sunday or any other day on which banks are authorized or",
          "bbox": [
            444.0,
            1349.0,
            3027.0,
            1394.0
          ],
          "confidence": 0.9931846261024475
        },
        {
          "text": "required to be closed in New York City, NY..",
          "bbox": [
            276.0,
            1407.0,
            1073.0,
            1449.0
          ],
          "confidence": 0.9924694299697876
        },
        {
          "text": "1.3 \"Calendar Quarter\"' means the consecutive three month period ending on one of March 31, June 30, September 30, or December 31.",
          "bbox": [
            446.0,
            1466.0,
            2934.0,
            1502.0
          ],
          "confidence": 0.9857224822044373
        },
        {
          "text": "1.4 \"Confidential Information\"' includes: (1) all information contained in documents marked \"confidential\" and disclosed by one Party (the",
          "bbox": [
            444.0,
            1517.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9882820248603821
        },
        {
          "text": "\"disclosing party\") to the other Party (the \"recipient party\") pursuant to this Agreement; (2) orally disclosed information which is disclosed by the",
          "bbox": [
            279.0,
            1573.0,
            3027.0,
            1619.0
          ],
          "confidence": 0.9915019869804382
        },
        {
          "text": "disclosing party to the recipient party pursuant to this Agreement, summarized in writing, identified as \"confidential\" and delivered to the recipient",
          "bbox": [
            277.0,
            1630.0,
            3029.0,
            1676.0
          ],
          "confidence": 0.9962403178215027
        },
        {
          "text": "party; and (3) all proprietary technical information, business and financial information, and all other information which a reasonable person would",
          "bbox": [
            277.0,
            1687.0,
            3029.0,
            1732.0
          ],
          "confidence": 0.9834481477737427
        },
        {
          "text": "treat confidentially that relates to the Development Products and disclosed from the disclosing party to the recipient party, whether or not the",
          "bbox": [
            277.0,
            1745.0,
            3027.0,
            1789.0
          ],
          "confidence": 0.9876152873039246
        },
        {
          "text": "information is marked as \"confidential.\" Notwithstanding anything to the contrary, CNS shall be permitted to make such disclosures as CNS",
          "bbox": [
            277.0,
            1798.0,
            3027.0,
            1844.0
          ],
          "confidence": 0.9905795454978943
        },
        {
          "text": "determines, in its sole discretion, is required pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof..",
          "bbox": [
            279.0,
            1857.0,
            2958.0,
            1899.0
          ],
          "confidence": 0.9846920371055603
        },
        {
          "text": "1.5 \"Development Fee'\" means 50% of the Net Sales for any Development Products in the Development Territory..",
          "bbox": [
            446.0,
            1908.0,
            2543.0,
            1957.0
          ],
          "confidence": 0.9791620373725891
        },
        {
          "text": "1.6 \"Development Products\" means: (i) Sublicensed Products, as defined in the Sublicense Agreement, in the field of pharmaceutical drug",
          "bbox": [
            448.0,
            1970.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9852625131607056
        },
        {
          "text": "products for the treatment of any viral infection in humans; and (ii) any other drug or product in the field of pharmaceutical drug products for the",
          "bbox": [
            279.0,
            2027.0,
            3027.0,
            2069.0
          ],
          "confidence": 0.9874441027641296
        },
        {
          "text": "treatment of any viral infection in humans that is licensed between WPD and MBI after this date..",
          "bbox": [
            279.0,
            2083.0,
            2077.0,
            2120.0
          ],
          "confidence": 0.984982430934906
        },
        {
          "text": "1.7 \"Development Territory\"' means (i) until the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense.",
          "bbox": [
            442.0,
            2134.0,
            3027.0,
            2180.0
          ],
          "confidence": 0.9841306209564209
        },
        {
          "text": "Agreement; and (ii) after the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement, other than Poland..",
          "bbox": [
            283.0,
            2195.0,
            2962.0,
            2237.0
          ],
          "confidence": 0.9880318641662598
        },
        {
          "text": "1",
          "bbox": [
            1641.0,
            2277.0,
            1670.0,
            2311.0
          ],
          "confidence": 0.9987025260925293
        },
        {
          "text": "Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020",
          "bbox": [
            332.0,
            4437.0,
            1421.0,
            4479.0
          ],
          "confidence": 0.9964609146118164
        }
      ],
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Revenue/Profit Sharing_0",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "\"Development Fee\" means 50% of the Net Sales for any Development Products in the Development Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "1.5 \"Development Fee'\" means 50% of the Net Sales for any Development Products in the Development Territory..",
          "bbox": [
            446.0,
            1908.0,
            2543.0,
            1957.0
          ],
          "confidence": 0.9791620373725891
        }
      ],
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "Thereafter, WPD shall furnish to CNS Development Fees no later than forty-five days after the end of each Calendar Quarter for the Sale of Development Products through the end of such Calendar Quarter and shall further furnish CNS with a written statement setting forth an accounting showing the calculation of the Development Fees.",
      "page_number": 1,
      "words": [
        {
          "text": "Development Product took place. Thereafter, WPD shall furnish to CNS Development Fees no later than forty-five days after the end of each",
          "bbox": [
            277.0,
            1491.0,
            3027.0,
            1533.0
          ],
          "confidence": 0.9914149641990662
        },
        {
          "text": "Calendar Quarter for the Sale of Development Products through the end of such Calendar Quarter and shall further furnish CNS with a written",
          "bbox": [
            279.0,
            1548.0,
            3027.0,
            1590.0
          ],
          "confidence": 0.998877227306366
        },
        {
          "text": "statement setting forth an accounting showing the calculation of the Development Fees..",
          "bbox": [
            277.0,
            1604.0,
            1919.0,
            1646.0
          ],
          "confidence": 0.9940059185028076
        }
      ],
      "multi_page": true,
      "part_of": 1,
      "nearby_headers": [
        {
          "text": "ARTICLE 2",
          "page": 1,
          "bbox": [
            1544.0,
            649.0,
            1767.0,
            687.0
          ]
        },
        {
          "text": "DEVELOPMENT AGREEMENT",
          "page": 1,
          "bbox": [
            1350.0,
            707.0,
            1954.0,
            744.0
          ]
        },
        {
          "text": "ARTICLE 3",
          "page": 1,
          "bbox": [
            1544.0,
            1661.0,
            1767.0,
            1699.0
          ]
        },
        {
          "text": "INFORMATION AND USE",
          "page": 1,
          "bbox": [
            1401.0,
            1718.0,
            1909.0,
            1754.0
          ]
        },
        {
          "text": "ARTICLE 4",
          "page": 1,
          "bbox": [
            1544.0,
            1997.0,
            1767.0,
            2036.0
          ]
        },
        {
          "text": "OTHER COMPENSATION",
          "page": 1,
          "bbox": [
            1399.0,
            2054.0,
            1910.0,
            2090.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Audit Rights_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "WPD shall, and shall cause its respective affiliates, to permit CNS and its respective designated representatives, at reasonable times and upon reasonable prior notice to such parties, to review the books and records of WPD and any of its affiliates and to discuss the affairs, finances and condition of such party and any of its affiliates with the officers of such entities and any of their affiliates in relation to their compliance with this section, as applicable.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1.",
          "bbox": [
            277.0,
            285.0,
            488.0,
            323.0
          ],
          "confidence": 0.9286127686500549
        },
        {
          "text": "Development Agreement",
          "bbox": [
            1421.0,
            342.0,
            1890.0,
            384.0
          ],
          "confidence": 0.9995174407958984
        },
        {
          "text": "This Development Agreement (the \"Agreement') dated as of March 20, 2020 (the \"Effective Date') is entered into by and between CNS",
          "bbox": [
            448.0,
            397.0,
            3027.0,
            439.0
          ],
          "confidence": 0.9855481386184692
        },
        {
          "text": "Pharmaceuticals, Inc. (\"CNS'), a Nevada corporation, having a business address of 2100 West Loop South, Suite 900, Houston, Texas 77027, and.",
          "bbox": [
            277.0,
            451.0,
            3029.0,
            497.0
          ],
          "confidence": 0.9846682548522949
        },
        {
          "text": "WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Zwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are",
          "bbox": [
            279.0,
            506.0,
            3029.0,
            552.0
          ],
          "confidence": 0.9871551990509033
        },
        {
          "text": "sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\".",
          "bbox": [
            279.0,
            566.0,
            1890.0,
            609.0
          ],
          "confidence": 0.9848995804786682
        },
        {
          "text": "RECITALS",
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ],
          "confidence": 0.9994499683380127
        },
        {
          "text": "WHEREAS, WPD is party to a sublicense agreement dated February 19, 2019 with Moleculin Biotech, Inc. (\"MBI) (the \"Sublicense",
          "bbox": [
            448.0,
            676.0,
            3025.0,
            718.0
          ],
          "confidence": 0.9924393892288208
        },
        {
          "text": "Agreement') to research and develop, manufacture, have manufactured, use, export/import, offer to sell and/or sell certain products for use in",
          "bbox": [
            279.0,
            735.0,
            3029.0,
            777.0
          ],
          "confidence": 0.9946522116661072
        },
        {
          "text": "certain territories;",
          "bbox": [
            277.0,
            795.0,
            605.0,
            831.0
          ],
          "confidence": 0.9829395413398743
        },
        {
          "text": "WHEREAS, WPD is developing certain anti-viral indications pursuant to the Sublicense Agreement; and",
          "bbox": [
            446.0,
            846.0,
            2402.0,
            890.0
          ],
          "confidence": 0.9923189878463745
        },
        {
          "text": "WHEREAS, CNS has agreed to fund a portion of the development of such indications in exchange for certain economic rights..",
          "bbox": [
            448.0,
            903.0,
            2791.0,
            945.0
          ],
          "confidence": 0.9883580207824707
        },
        {
          "text": "NOW, THEREFORE, in consideration of the covenants, conditions and agreements hereinafter set forth, and other valuable consideration,",
          "bbox": [
            440.0,
            958.0,
            3025.0,
            1001.0
          ],
          "confidence": 0.9950847029685974
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, WPD and CNS hereby agree as follows:.",
          "bbox": [
            279.0,
            1016.0,
            2170.0,
            1058.0
          ],
          "confidence": 0.9944117665290833
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ],
          "confidence": 0.9448484778404236
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ],
          "confidence": 0.9979127645492554
        },
        {
          "text": "1.1 \"Approval Achievement Date\"' means the earlier of the: (i) date on which WPD receives marketing approval for a Development Product",
          "bbox": [
            446.0,
            1180.0,
            3029.0,
            1226.0
          ],
          "confidence": 0.9900801777839661
        },
        {
          "text": "Development Fees hereunder of $1.0 million..",
          "bbox": [
            279.0,
            1296.0,
            1100.0,
            1336.0
          ],
          "confidence": 0.9840089678764343
        },
        {
          "text": "1.2 \"Business Day\"' means any day other than a day which is a Saturday, a Sunday or any other day on which banks are authorized or",
          "bbox": [
            444.0,
            1349.0,
            3027.0,
            1394.0
          ],
          "confidence": 0.9931846261024475
        },
        {
          "text": "required to be closed in New York City, NY..",
          "bbox": [
            276.0,
            1407.0,
            1073.0,
            1449.0
          ],
          "confidence": 0.9924694299697876
        },
        {
          "text": "1.3 \"Calendar Quarter\"' means the consecutive three month period ending on one of March 31, June 30, September 30, or December 31.",
          "bbox": [
            446.0,
            1466.0,
            2934.0,
            1502.0
          ],
          "confidence": 0.9857224822044373
        },
        {
          "text": "1.4 \"Confidential Information\"' includes: (1) all information contained in documents marked \"confidential\" and disclosed by one Party (the",
          "bbox": [
            444.0,
            1517.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9882820248603821
        },
        {
          "text": "\"disclosing party\") to the other Party (the \"recipient party\") pursuant to this Agreement; (2) orally disclosed information which is disclosed by the",
          "bbox": [
            279.0,
            1573.0,
            3027.0,
            1619.0
          ],
          "confidence": 0.9915019869804382
        },
        {
          "text": "disclosing party to the recipient party pursuant to this Agreement, summarized in writing, identified as \"confidential\" and delivered to the recipient",
          "bbox": [
            277.0,
            1630.0,
            3029.0,
            1676.0
          ],
          "confidence": 0.9962403178215027
        },
        {
          "text": "party; and (3) all proprietary technical information, business and financial information, and all other information which a reasonable person would",
          "bbox": [
            277.0,
            1687.0,
            3029.0,
            1732.0
          ],
          "confidence": 0.9834481477737427
        },
        {
          "text": "treat confidentially that relates to the Development Products and disclosed from the disclosing party to the recipient party, whether or not the",
          "bbox": [
            277.0,
            1745.0,
            3027.0,
            1789.0
          ],
          "confidence": 0.9876152873039246
        },
        {
          "text": "information is marked as \"confidential.\" Notwithstanding anything to the contrary, CNS shall be permitted to make such disclosures as CNS",
          "bbox": [
            277.0,
            1798.0,
            3027.0,
            1844.0
          ],
          "confidence": 0.9905795454978943
        },
        {
          "text": "determines, in its sole discretion, is required pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof..",
          "bbox": [
            279.0,
            1857.0,
            2958.0,
            1899.0
          ],
          "confidence": 0.9846920371055603
        },
        {
          "text": "1.5 \"Development Fee'\" means 50% of the Net Sales for any Development Products in the Development Territory..",
          "bbox": [
            446.0,
            1908.0,
            2543.0,
            1957.0
          ],
          "confidence": 0.9791620373725891
        },
        {
          "text": "1.6 \"Development Products\" means: (i) Sublicensed Products, as defined in the Sublicense Agreement, in the field of pharmaceutical drug",
          "bbox": [
            448.0,
            1970.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9852625131607056
        },
        {
          "text": "products for the treatment of any viral infection in humans; and (ii) any other drug or product in the field of pharmaceutical drug products for the",
          "bbox": [
            279.0,
            2027.0,
            3027.0,
            2069.0
          ],
          "confidence": 0.9874441027641296
        },
        {
          "text": "treatment of any viral infection in humans that is licensed between WPD and MBI after this date..",
          "bbox": [
            279.0,
            2083.0,
            2077.0,
            2120.0
          ],
          "confidence": 0.984982430934906
        },
        {
          "text": "1.7 \"Development Territory\"' means (i) until the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense.",
          "bbox": [
            442.0,
            2134.0,
            3027.0,
            2180.0
          ],
          "confidence": 0.9841306209564209
        },
        {
          "text": "Agreement; and (ii) after the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement, other than Poland..",
          "bbox": [
            283.0,
            2195.0,
            2962.0,
            2237.0
          ],
          "confidence": 0.9880318641662598
        },
        {
          "text": "1",
          "bbox": [
            1641.0,
            2277.0,
            1670.0,
            2311.0
          ],
          "confidence": 0.9987025260925293
        },
        {
          "text": "Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020",
          "bbox": [
            332.0,
            4437.0,
            1421.0,
            4479.0
          ],
          "confidence": 0.9964609146118164
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1548.0,
            623.0,
            1762.0,
            660.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 0,
          "bbox": [
            1542.0,
            1069.0,
            1767.0,
            1107.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1515.0,
            1127.0,
            1794.0,
            1166.0
          ]
        }
      ]
    },
    {
      "id": "CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "WPD shall, and shall cause its respective affiliates, to permit CNS and its respective designated representatives, at reasonable times and upon reasonable prior notice to such parties, to review the books and records of WPD and any of its affiliates and to discuss the affairs, finances and condition of such party and any of its affiliates with the officers of such entities and any of their affiliates in relation to their compliance with this section, as applicable.",
      "page_number": 1,
      "words": [
        {
          "text": "1.8 \"Net Sales\"' shall be defined in the same way as defined in Sections 6.1 (a)-(f) of the Sublicense Agreement, as applicable only to the",
          "bbox": [
            450.0,
            258.0,
            3025.0,
            300.0
          ],
          "confidence": 0.9870871305465698
        },
        {
          "text": "Agreement.",
          "bbox": [
            283.0,
            373.0,
            498.0,
            411.0
          ],
          "confidence": 0.999921977519989
        },
        {
          "text": "1.9 \"Phase II Milestone Payment' means the completion by WPD of a Phase II Study in one of the countries included within the.",
          "bbox": [
            442.0,
            422.0,
            3027.0,
            468.0
          ],
          "confidence": 0.989180862903595
        },
        {
          "text": "Development Territory, which clinical trial meets all endpoints and is sufficient to form the basis of an application for approval of a Development.",
          "bbox": [
            279.0,
            482.0,
            3029.0,
            524.0
          ],
          "confidence": 0.9877327680587769
        },
        {
          "text": "Product in one Development Territory other than Poland..",
          "bbox": [
            281.0,
            541.0,
            1336.0,
            577.0
          ],
          "confidence": 0.9897002577781677
        },
        {
          "text": "1.10 \"Sale\", \"Sells\", \"Sold\"' means the transfer or disposition of a Development Product, for value, to a person or entity for end use.",
          "bbox": [
            448.0,
            594.0,
            2880.0,
            636.0
          ],
          "confidence": 0.9865548610687256
        },
        {
          "text": "ARTICLE 2",
          "bbox": [
            1544.0,
            649.0,
            1767.0,
            687.0
          ],
          "confidence": 0.9926357269287109
        },
        {
          "text": "DEVELOPMENT AGREEMENT",
          "bbox": [
            1350.0,
            707.0,
            1954.0,
            744.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "take, or cause to be taken, all actions, and to do or cause to be done, all things necessary, proper or desirable or advisable under applicable laws to.",
          "bbox": [
            277.0,
            817.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9957833290100098
        },
        {
          "text": "develop and commercialize the Development Products, with a goal of eventual approval of Development Products in the Development Territory. In",
          "bbox": [
            281.0,
            875.0,
            3025.0,
            916.0
          ],
          "confidence": 0.9946615695953369
        },
        {
          "text": "exchange for the payment by WPD of the Development Fee to CNS, CNS hereby agrees to pay WPD the following payments: (i) within thirty",
          "bbox": [
            277.0,
            930.0,
            3027.0,
            976.0
          ],
          "confidence": 0.9964195489883423
        },
        {
          "text": "Business Days from the date of this Agreement, CNS will make an upfront payment of $225,000 to WPD; and (ii) within thirty days of the verified",
          "bbox": [
            279.0,
            985.0,
            3027.0,
            1027.0
          ],
          "confidence": 0.9940240979194641
        },
        {
          "text": "achievement of the Phase II Milestone, (such verification shall be conducted by an independent third party mutually acceptable to the parties",
          "bbox": [
            277.0,
            1042.0,
            3027.0,
            1085.0
          ],
          "confidence": 0.9979512095451355
        },
        {
          "text": "hereto), CNS will make a payment of $775,000 to WPD.",
          "bbox": [
            277.0,
            1098.0,
            1285.0,
            1142.0
          ],
          "confidence": 0.9748402833938599
        },
        {
          "text": "2.2 If after three years from the Effective Date of this Development Agreement, WPD fails to use commercially reasonable efforts as set",
          "bbox": [
            444.0,
            1155.0,
            3030.0,
            1197.0
          ],
          "confidence": 0.9947488307952881
        },
        {
          "text": "forth in section 2.1 above, CNS shall have the right to terminate this Agreement pursuant to the terms specified in Section 6.2 below, and CNS shall",
          "bbox": [
            279.0,
            1212.0,
            3029.0,
            1254.0
          ],
          "confidence": 0.9961009621620178
        },
        {
          "text": "be entitled to the return of any payments made hereunder. For the purpose of this clause, if WPD has expended the funds provided by CNS",
          "bbox": [
            274.0,
            1263.0,
            3029.0,
            1314.0
          ],
          "confidence": 0.9811084866523743
        },
        {
          "text": "pursuant to section 2.1 above on developing anti-viral indications (including all direct and indirect costs of such development), it will be deemed to.",
          "bbox": [
            277.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9939746260643005
        },
        {
          "text": "have used commercially reasonable efforts in good faith.",
          "bbox": [
            276.0,
            1380.0,
            1329.0,
            1424.0
          ],
          "confidence": 0.9941956400871277
        },
        {
          "text": "2.3 The first Development Fees payment shall be due forty-five days after the end of the Calendar Quarter in which the first Sale of a.",
          "bbox": [
            440.0,
            1431.0,
            3029.0,
            1482.0
          ],
          "confidence": 0.992863655090332
        },
        {
          "text": "Development Product took place. Thereafter, WPD shall furnish to CNS Development Fees no later than forty-five days after the end of each",
          "bbox": [
            277.0,
            1491.0,
            3027.0,
            1533.0
          ],
          "confidence": 0.9914149641990662
        },
        {
          "text": "Calendar Quarter for the Sale of Development Products through the end of such Calendar Quarter and shall further furnish CNS with a written",
          "bbox": [
            279.0,
            1548.0,
            3027.0,
            1590.0
          ],
          "confidence": 0.998877227306366
        },
        {
          "text": "statement setting forth an accounting showing the calculation of the Development Fees..",
          "bbox": [
            277.0,
            1604.0,
            1919.0,
            1646.0
          ],
          "confidence": 0.9940059185028076
        },
        {
          "text": "ARTICLE 3",
          "bbox": [
            1544.0,
            1661.0,
            1767.0,
            1699.0
          ],
          "confidence": 0.9958580732345581
        },
        {
          "text": "INFORMATION AND USE",
          "bbox": [
            1401.0,
            1718.0,
            1909.0,
            1754.0
          ],
          "confidence": 0.9995668530464172
        },
        {
          "text": "Sublicense Agreement related to the Development Products on a quarterly basis..",
          "bbox": [
            277.0,
            1825.0,
            1782.0,
            1873.0
          ],
          "confidence": 0.9869390726089478
        },
        {
          "text": "3.2 The Parties agree to a mutual exchange of any data, information or know-how resulting from the research and development of the.",
          "bbox": [
            444.0,
            1882.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.9899076223373413
        },
        {
          "text": "Development Products.",
          "bbox": [
            277.0,
            1939.0,
            712.0,
            1985.0
          ],
          "confidence": 0.9925432801246643
        },
        {
          "text": "ARTICLE 4",
          "bbox": [
            1544.0,
            1997.0,
            1767.0,
            2036.0
          ],
          "confidence": 0.9490203857421875
        },
        {
          "text": "OTHER COMPENSATION",
          "bbox": [
            1399.0,
            2054.0,
            1910.0,
            2090.0
          ],
          "confidence": 0.9996956586837769
        },
        {
          "text": "4.1 If MBI exercises its right to terminate the Sublicense Agreement in whole, or to remove a portion of the sublicensed subject matter that.",
          "bbox": [
            444.0,
            2105.0,
            3029.0,
            2153.0
          ],
          "confidence": 0.9973670244216919
        },
        {
          "text": "relates to some or all of the Development Products, by paying to WPD the Buyback Consideration (as defined in the Sublicense Agreement), wPD",
          "bbox": [
            276.0,
            2165.0,
            3027.0,
            2209.0
          ],
          "confidence": 0.9869776964187622
        },
        {
          "text": "agrees that CNS shall receive the greater of (i) 50% of the Buyback Consideration that is attributable to the field of anti-viral pharmaceutical drug",
          "bbox": [
            279.0,
            2222.0,
            3027.0,
            2266.0
          ],
          "confidence": 0.993865966796875
        },
        {
          "text": "products for humans (such attribution to be mutually agreed upon by the Parties), and (ii) the amounts actually provided to WPD pursuant to.",
          "bbox": [
            277.0,
            2279.0,
            3029.0,
            2321.0
          ],
          "confidence": 0.9830725789070129
        },
        {
          "text": "Section 2.1 of this Agreement.",
          "bbox": [
            281.0,
            2337.0,
            837.0,
            2374.0
          ],
          "confidence": 0.989253044128418
        },
        {
          "text": "2",
          "bbox": [
            1642.0,
            2416.0,
            1673.0,
            2454.0
          ],
          "confidence": 0.9953086972236633
        },
        {
          "text": "Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020",
          "bbox": [
            332.0,
            4437.0,
            1421.0,
            4479.0
          ],
          "confidence": 0.9957674741744995
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "ARTICLE 2",
          "page": 1,
          "bbox": [
            1544.0,
            649.0,
            1767.0,
            687.0
          ]
        },
        {
          "text": "DEVELOPMENT AGREEMENT",
          "page": 1,
          "bbox": [
            1350.0,
            707.0,
            1954.0,
            744.0
          ]
        },
        {
          "text": "ARTICLE 3",
          "page": 1,
          "bbox": [
            1544.0,
            1661.0,
            1767.0,
            1699.0
          ]
        },
        {
          "text": "INFORMATION AND USE",
          "page": 1,
          "bbox": [
            1401.0,
            1718.0,
            1909.0,
            1754.0
          ]
        },
        {
          "text": "ARTICLE 4",
          "page": 1,
          "bbox": [
            1544.0,
            1997.0,
            1767.0,
            2036.0
          ]
        },
        {
          "text": "OTHER COMPENSATION",
          "page": 1,
          "bbox": [
            1399.0,
            2054.0,
            1910.0,
            2090.0
          ]
        }
      ]
    }
  ]
}